English español

Repositorio de la Universidad de Oviedo > Producción Bibliográfica de UniOvi: RECOPILA > Artículos >

Use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10651/43849

Título : X-linked hypophosphatemia and growth
Autor(es) y otros: Fuente Pérez, Rocío
Gil Peña, Helena
Claramunt Taberner, Debora
Hernández Frías, Olaya
Fernández Iglesias, Ángela
Alonso Durán, Laura
Rodríguez Rubio, Enrique
Santos Rodríguez, Fernando
Palabras clave: XLH
Fecha de publicación : 27-ene-2017
Editorial : Springer US
Versión del editor: http://dx.doi.org/10.1007/s11154-017-9408-1
Citación : Reviews in Endocrine and Metabolic Disorders, 18(1), p. 107-115 (2017);doi: 10.1007/s11154-017-9408-1
Descripción física: p. 107–115
Resumen : X-Linked hypophosphatemia (XLH) is the most common form of hereditary rickets caused by loss-of function mutations in the PHEX gene. XLH is characterized by hypophosphatemia secondary to renal phosphate wasting, inappropriately low concentrations of 1,25 dihydroxyvitamin D and high circulating levels of fibroblast growth factor 23 (FGF23). Short stature and rachitic osseous lesions are characteristic phenotypic findings of XLH although the severity of these manifestations is highly variable among patients. The degree of growth impairment is not dependent on the magnitude of hypophosphatemia or the extent of legs´ bowing and height is not normalized by chronic administration of phosphate supplements and 1α hydroxyvitamin D derivatives. Treatment with growth hormone accelerates longitudinal growth rate but there is still controversy regarding the potential risk of increasing bone deformities and body disproportion. Treatments aimed at blocking FGF23 action are promising, but information is lacking on the consequences of counteracting FGF23 during the growing period. This review summarizes current knowledge on phosphorus metabolism in XLH, presents updated information on XLH and growth, including the effects of FGF23 on epiphyseal growth plate of the Hyp mouse, an animal model of the disease, and discusses growth hormone and novel FGF23 related therapies.
Fecha fin embargo: 2018-01-27
URI : http://hdl.handle.net/10651/43849
ISSN : 1389-9155
Aparece en las colecciones: Medicina
Investigaciones y Documentos OpenAIRE

Ficheros en este ítem:

Fichero Descripción Tamaño Formato
erratum.pdf184,04 kBAdobe PDFVisualizar/Abrir
RevEndocrMetabDisord_Fuente Rocio.pdf911,09 kBAdobe PDFVisualizar/Abrir

Exportar a Mendeley

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons
Creative Commons

Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.


Base de Datos de Autoridades Biblioteca Universitaria Consultas / Sugerencias